Gilead Sciences (NASDAQ:GILD) Given New $130.00 Price Target at The Goldman Sachs Group

Gilead Sciences (NASDAQ:GILD) had its price objective boosted by analysts at The Goldman Sachs Group from $125.00 to $130.00 in a note issued to investors on Friday,MarketScreener reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target indicates a potential downside of 5.81% from the stock’s previous close.

GILD has been the subject of a number of other reports. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Truist Financial lifted their price target on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Mizuho lifted their price target on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Finally, Leerink Partners lifted their price target on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $157.35.

Gilead Sciences Stock Down 0.4%

GILD opened at $138.02 on Friday. The company has a market capitalization of $171.31 billion, a P/E ratio of 20.28, a P/E/G ratio of 1.86 and a beta of 0.39. The firm’s fifty day moving average price is $144.65 and its two-hundred day moving average price is $131.10. Gilead Sciences has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue was up 4.7% on a year-over-year basis. During the same period last year, the business earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts anticipate that Gilead Sciences will post 7.95 EPS for the current year.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer directly owned 167,779 shares in the company, valued at approximately $25,910,110.97. The trade was a 1.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 299,280 shares of company stock valued at $42,920,450 over the last 90 days. 0.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Paulson Wealth Management Inc. grew its position in shares of Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the period. Essex Financial Services Inc. grew its position in shares of Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares during the period. Alpha Cubed Investments LLC grew its position in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the period. Personal CFO Solutions LLC grew its position in shares of Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares during the period. Finally, Moss Adams Wealth Advisors LLC grew its position in shares of Gilead Sciences by 1.7% in the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead announced it has received all required regulatory approvals for its acquisition of Arcellx and has extended the tender offer expiration — a strategic bolt‑on to its cell therapy/oncology pipeline that reduces deal execution risk. Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
• Positive Sentiment: Wells Fargo reiterated a buy rating on Gilead, reinforcing institutional confidence in the company’s longer‑term fundamentals and valuation. Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)
• Positive Sentiment: Government/public‑health support expanded for lenacapavir (Gilead’s HIV prevention product) via a U.S. State Department/Global Fund partnership to distribute doses, which supports uptake and public‑sector demand. US-Led Partnership To Provide 1 Mln Lenacapavir To Help End HIV Transmission
• Neutral Sentiment: Two insiders, including the CFO, reported small share sales executed under pre‑arranged Rule 10b5‑1 plans — typical liquidity‑taking rather than an unusual red flag. SEC Form 4 (Andrew D. Dickinson)
• Neutral Sentiment: Gilead is approaching its quarterly earnings release window, which typically raises volatility as investors reprice based on guidance and product trends. Gilead Sciences (GILD) Expected to Announce Quarterly Earnings on Thursday
• Neutral Sentiment: Media/valuation pieces and trending‑stock attention are drawing investor focus but have not changed core fundamentals. Gauging Gilead Sciences (GILD) Valuation After Strong Multi‑Year Shareholder Returns
• Negative Sentiment: RBC reported weaker‑than‑expected persistence for Gilead’s newly launched HIV drug nine months post‑launch — a potential headwind to growth assumptions for the franchise. Gilead Sciences’ HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says
• Negative Sentiment: Zacks Research trimmed Q1–Q4 FY2026 EPS forecasts, lowering near‑term earnings expectations and adding downside risk to consensus. Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Broader health‑care stocks were softer in late trading, which amplified downward pressure on Gilead despite company‑specific positives. Sector Update: Health Care Stocks Decline Late Afternoon

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.